Issuer Free Writing Prospectus dated June 26, 2024 Filed Pursuant to Rule 433 Relating to the Preliminary Prospectus dated June 21, 2024 and Registration Statement No. 333-279119

## TAMBORAN RESOURCES CORPORATION

This free writing prospectus relates only to the shares of common stock described below and should be read together with the preliminary prospectus, subject to completion, dated June 21, 2024 (the "Preliminary Prospectus"), of Tamboran Resources Corporation (the "Company") relating to this offering. The information in this free writing prospectus updates and supersedes the information in the Preliminary Prospectus to the extent that it is inconsistent therewith, or prepared based on assumptions that are inconsistent with the information below.

The following information updates the information contained in the preliminary prospectus.

Common stock offered by us

Option to purchase additional shares

Common stock to be outstanding immediately after completion of this offering

Expected Public Offering Price (per share):

Use of proceeds

3,125,000 shares (or 3,593,750 shares if the underwriters' option to purchase additional shares is exercised in full).

We have granted the underwriters a 30 day option to purchase up to an aggregate of 468,750 additional shares of our common stock.

\$24.00

14,228,024 shares (or 14,696,774 shares if the underwriters' option to purchase additional shares is exercised in full), which includes (i) the conversion of the Convertible Note into an aggregate of 489,088 shares of common stock at a conversion price of \$19.20 (assuming the expected public offering price of \$24.00 per share), and (ii) the issuance of 312,500 shares of our common stock (assuming the expected public offering price of \$24.00 per share) in connection with the Daly Waters Placement.

We expect to receive \$70.1 million of net proceeds from the sale of our common stock in this offering, based upon the expected public offering price of \$24.00, after deducting underwriting discounts and estimated offering expenses (or \$80.6 million if the underwriters' option to purchase additional shares is exercised in full).

- We estimate capital needs of approximately \$125 million to \$165 million to fund our initial development phase. As previously stated in this
  prospectus, we expect to fund our capital program with proceeds from this offering, cash on hand, as well as additional future capital raising
  efforts.
- H&P has confirmed its election to convert the Convertible Note into shares of common stock at the conversion price based on the initial public
  offering price of our common stock in this offering, provided that the gross proceeds resulting from the offering are at least \$75 million.
- Daly Waters has confirmed its agreement to accept \$7.5 million in shares of our common stock at the initial public offering price in satisfaction of certain payment obligations under the TB1 Joint Venture Agreement, provided that the gross proceeds resulting from the offering are at least \$75 million.